The World Health Organization applauded the decision this week by Abbott Laboratories to lower the price of its second-line drug lopinavir/ritonavir (marketed as Kaletra or Aluvia) by 55 percent in more than 40 developing countries. As more and more people become resistant to first-line antiretrovirals, demand for newer drugs is increasing.